{"id":4930,"date":"2025-04-02T11:35:44","date_gmt":"2025-04-02T16:35:44","guid":{"rendered":"https:\/\/lsom.uthscsa.edu\/neurology\/?page_id=4930"},"modified":"2025-04-02T17:22:37","modified_gmt":"2025-04-02T22:22:37","slug":"neuromuscular-research-3","status":"publish","type":"page","link":"https:\/\/lsom.uthscsa.edu\/neurology\/neuromuscular-research-3\/","title":{"rendered":"Neuromuscular Research"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row][vc_column width=&#8221;2\/3&#8243;][vc_column_text css=&#8221;&#8221;]<\/p>\n<h1><b><span style=\"color: #993300\">Expertise:<\/span><\/b><\/h1>\n<p>We offer a robust research program including many Clinical trials and innovative research for patients with ALS, myasthenia gravis, muscular dystrophies, and peripheral neuropathy. We are an active member of the Northeast ALS Consortium (NEALS) and the Muscle Study Group (MSG).\u00a0 We are currently part of the Healey Platform study in collaboration with Massachusetts General Hospital and NEALS.\u00a0 We are also members of the CReATe Consortium which is a NIH funded project through the University of Miami for patients with motor neuron disorders.[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column width=&#8221;5\/6&#8243;]<ul class=\"accordion accordion-block-type\" data-accordion data-allow-all-closed=\"true\"><li class=\"accordion-item is-active\" data-accordion-item><a href=\"#\" class=\"accordion-title\"><h2>CReATe  CAPTURE - ALS<\/h2><\/a><div class=\"accordion-content\" data-tab-content><p><p style=\"text-align: left\"><img loading=\"lazy\" decoding=\"async\" class=\"alignleft wp-image-1214\" src=\"https:\/\/lsom.uthscsa.edu\/neurology\/wp-content\/uploads\/sites\/105\/2019\/08\/carlaynejackson-322x450.jpg\" alt=\"Caralyne Jackson, MD\" width=\"104\" height=\"145\" srcset=\"https:\/\/lsom.uthscsa.edu\/neurology\/wp-content\/uploads\/sites\/105\/2019\/08\/carlaynejackson-322x450.jpg 322w, https:\/\/lsom.uthscsa.edu\/neurology\/wp-content\/uploads\/sites\/105\/2019\/08\/carlaynejackson.jpg 429w\" sizes=\"auto, (max-width: 104px) 100vw, 104px\" \/> \u00a0<\/p>\n<p style=\"text-align: left\"><em><strong>Principal Investigator:<\/strong><\/em><br \/>Carlayne Jackson, MD<\/p>\n<p><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT03489278\">https:\/\/clinicaltrials.gov\/study\/NCT03489278<\/a><\/p>\n<p><strong>Type of Study:<\/strong><br \/>Registry\/Observational<\/p>\n<p><strong>Summary<\/strong><br \/>The purpose of the Clinical Procedures To Support Research (CAPTURE) study is to utilize information collected in the medical record to learn more about a disease called amyotrophic lateral sclerosis (ALS) and related disorders. The study will consent patients with ALS or related disorders that are receiving care at a clinical center in the CReATe consortium that uses Epic as its electronic health record (EHR) system. The study aims to systematically gather a clinical dataset through the EHR using a standardized approach to characterize the natural history of ALS and related diseases.<\/p>\n<p><strong>Link to Sponsor&#8217;s Website:<br \/><\/strong><a href=\"https:\/\/create.rarediseasesnetwork.org\/research-studies\">https:\/\/create.rarediseasesnetwork.org\/research-studies<\/a><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignright wp-image-3013\" src=\"https:\/\/lsom.uthscsa.edu\/neurology\/wp-content\/uploads\/sites\/105\/2022\/11\/299_10A_13070105_1248700972_2.jpg\" alt=\"Randee Kent\" width=\"104\" height=\"145\" \/><\/p>\n<p style=\"text-align: right\"><em><strong>Study Coordinator:<\/strong><\/em><br \/>Randee Kent<br \/>Office: 210-450-0524<br \/>Email:\u00a0<a href=\"mailto:kentbaron@uthscsa.edu\">kentbaron@uthscsa.edu<\/a><\/p><\/div><\/li><li class=\"accordion-item \" data-accordion-item><a href=\"#\" class=\"accordion-title\"><h2>HEALEY ALS Platform Regimen G<\/h2><\/a><div class=\"accordion-content\" data-tab-content><p><p style=\"text-align: left\"><img loading=\"lazy\" decoding=\"async\" class=\"alignleft wp-image-1214\" src=\"https:\/\/lsom.uthscsa.edu\/neurology\/wp-content\/uploads\/sites\/105\/2019\/08\/carlaynejackson-322x450.jpg\" alt=\"Caralyne Jackson, MD\" width=\"104\" height=\"145\" srcset=\"https:\/\/lsom.uthscsa.edu\/neurology\/wp-content\/uploads\/sites\/105\/2019\/08\/carlaynejackson-322x450.jpg 322w, https:\/\/lsom.uthscsa.edu\/neurology\/wp-content\/uploads\/sites\/105\/2019\/08\/carlaynejackson.jpg 429w\" sizes=\"auto, (max-width: 104px) 100vw, 104px\" \/> \u00a0<\/p>\n<p style=\"text-align: left\"><em><strong>Principal Investigator:<\/strong><\/em><br \/>Carlayne Jackson, MD<\/p>\n<p><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05842941\">https:\/\/clinicaltrials.gov\/study\/NCT05842941<\/a><\/p>\n<p><strong>Type of Study:<\/strong><br \/>Interventional\/Randomized Control<\/p>\n<p><strong>Summary<\/strong><br \/>The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. This trial is designed as a perpetual platform trial. This means that there is a single Master Protocol dictating the conduct of the trial. The HEALEY ALS Platform Trial Master Protocol is registered as NCT04297683. Once a participant enrolls into the Master Protocol and meets all eligibility criteria, the participant will be eligible to be randomized into any currently enrolling regimen. All participants will have an equal chance of being randomized to any currently enrolling regimen. \u00a0Regimen G will evaluate the safety and efficacy of a single study drug, DNL343, in participants with ALS.<\/p>\n<p><strong>Link to Sponsor&#8217;s Website:<br \/><\/strong><a href=\"https:\/\/www.massgeneral.org\/assets\/mgh\/pdf\/neurology\/als\/generalplatform.june2023.pdf\">https:\/\/www.massgeneral.org\/assets\/mgh\/pdf\/neurology\/als\/generalplatform.june2023.pdf<\/a><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignright wp-image-3013\" src=\"https:\/\/lsom.uthscsa.edu\/neurology\/wp-content\/uploads\/sites\/105\/2022\/11\/299_10A_13070105_1248700972_2.jpg\" alt=\"Randee Kent\" width=\"104\" height=\"145\" \/><\/p>\n<p style=\"text-align: right\"><em><strong>Study Coordinator:<\/strong><\/em><br \/>Randee Kent<br \/>Office: 210-450-0524<br \/>Email:\u00a0<a href=\"mailto:kentbaron@uthscsa.edu\">kentbaron@uthscsa.edu<\/a><\/p><\/div><\/li><li class=\"accordion-item \" data-accordion-item><a href=\"#\" class=\"accordion-title\"><h2>HEALEY ALS Platform Regimen F<\/h2><\/a><div class=\"accordion-content\" data-tab-content><p><p style=\"text-align: left\"><img loading=\"lazy\" decoding=\"async\" class=\"alignleft wp-image-1214\" src=\"https:\/\/lsom.uthscsa.edu\/neurology\/wp-content\/uploads\/sites\/105\/2019\/08\/carlaynejackson-322x450.jpg\" alt=\"Caralyne Jackson, MD\" width=\"104\" height=\"145\" srcset=\"https:\/\/lsom.uthscsa.edu\/neurology\/wp-content\/uploads\/sites\/105\/2019\/08\/carlaynejackson-322x450.jpg 322w, https:\/\/lsom.uthscsa.edu\/neurology\/wp-content\/uploads\/sites\/105\/2019\/08\/carlaynejackson.jpg 429w\" sizes=\"auto, (max-width: 104px) 100vw, 104px\" \/> \u00a0<\/p>\n<p style=\"text-align: left\"><em><strong>Principal Investigator:<\/strong><\/em><br \/>Carlayne Jackson, MD<\/p>\n<p><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05740813\">https:\/\/clinicaltrials.gov\/study\/NCT05740813<\/a><\/p>\n<p><strong>Type of Study:<\/strong><br \/>Interventional \/ Randomized Control<\/p>\n<p><strong>Summary<\/strong><br \/>The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. This trial is designed as a perpetual platform trial. This means that there is a single Master Protocol dictating the conduct of the trial. The HEALEY ALS Platform Trial Master Protocol is registered as NCT04297683. Once a participant enrolls into the Master Protocol and meets all eligibility criteria, the participant will be eligible to be randomized into any currently enrolling regimen. All participants will have an equal chance of being randomized to any currently enrolling regimen. Regimen F will evaluate the safety and efficacy of a single study drug, ABBV-CLS-7262, in participants with ALS.<\/p>\n<p><strong>Link to Sponsor&#8217;s Website:<br \/><\/strong><a href=\"https:\/\/www.massgeneral.org\/assets\/mgh\/pdf\/neurology\/als\/generalplatform.june2023.pdf\">https:\/\/www.massgeneral.org\/assets\/mgh\/pdf\/neurology\/als\/generalplatform.june2023.pdf<\/a><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignright wp-image-3013\" src=\"https:\/\/lsom.uthscsa.edu\/neurology\/wp-content\/uploads\/sites\/105\/2022\/11\/299_10A_13070105_1248700972_2.jpg\" alt=\"Randee Kent\" width=\"104\" height=\"145\" \/><\/p>\n<p style=\"text-align: right\"><em><strong>Study Coordinator:<\/strong><\/em><br \/>Randee Kent<br \/>Office: 210-450-0524<br \/>Email:\u00a0<a href=\"mailto:kentbaron@uthscsa.edu\">kentbaron@uthscsa.edu<\/a><\/p><\/div><\/li><li class=\"accordion-item \" data-accordion-item><a href=\"#\" class=\"accordion-title\"><h2>MOVE+<\/h2><\/a><div class=\"accordion-content\" data-tab-content><p><p style=\"text-align: left\"><img loading=\"lazy\" decoding=\"async\" class=\"alignleft wp-image-3425\" src=\"https:\/\/lsom.uthscsa.edu\/neurology\/wp-content\/uploads\/sites\/105\/2023\/05\/3A4_19_13070105_1848520645_2.jpg\" alt=\"Matthew WIcklund, MD\" width=\"104\" height=\"145\" \/> \u00a0<\/p>\n<p style=\"text-align: left\"><em><strong>Principal Investigator:<\/strong><\/em><br \/>Matthew Wicklund, MD<\/p>\n<p><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT04635891\">https:\/\/clinicaltrials.gov\/study\/NCT04635891<\/a><\/p>\n<p><strong>Type of Study:<\/strong><br \/>Observational\/Natural History<\/p>\n<p><strong>Summary<\/strong><br \/>The primary goal of this proposal is to collect motor and functional outcomes specific to FSHD over time. By collecting measures specific to FSHD, this will help ensure the best level of clinical care is being provided. Also, the hope is to speed up drug development by gaining a better understanding of how having FSHD impacts motor function and other health outcomes (i.e. breathing, wheelchair use, etc.) and how big a change in motor function would be clinically meaningful to those with FSHD. Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD) will have approximately 450 FSHD participants followed for a minimum of 3 years. A subset of MOVE FSHD participants, approximately 200, will participate in the MOVE+ sub-study which includes whole body MRI and muscle biopsy.<\/p>\n<p><strong>Link to Sponsor&#8217;s Website:<br \/><\/strong><a href=\"https:\/\/www.fshdsociety.org\/2021\/07\/26\/anyone-can-move-for-fshd-research\/\">https:\/\/www.fshdsociety.org\/2021\/07\/26\/anyone-can-move-for-fshd-research\/<\/a><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignright wp-image-4514\" src=\"https:\/\/lsom.uthscsa.edu\/neurology\/wp-content\/uploads\/sites\/105\/2024\/10\/Marlon-Tamayo-Muradas.jpg\" alt=\"\" width=\"104\" height=\"145\" \/><\/p>\n<p style=\"text-align: right\"><em><strong>Study Coordinator:<\/strong><\/em><br \/>Marlon Tamayo<br \/>Office: 210-450-7370<br \/>Email:\u00a0<a href=\"mailto:tomayomurada@uthscsa.edu\">tomayomurada@uthscsa.edu<\/a><\/p><\/div><\/li><li class=\"accordion-item \" data-accordion-item><a href=\"#\" class=\"accordion-title\"><h2>SUMMIT<\/h2><\/a><div class=\"accordion-content\" data-tab-content><p><p style=\"text-align: left\"><img loading=\"lazy\" decoding=\"async\" class=\"alignleft wp-image-3425\" src=\"https:\/\/lsom.uthscsa.edu\/neurology\/wp-content\/uploads\/sites\/105\/2023\/05\/3A4_19_13070105_1848520645_2.jpg\" alt=\"Matthew WIcklund, MD\" width=\"104\" height=\"145\" \/> \u00a0<\/p>\n<p style=\"text-align: left\"><em><strong>Principal Investigator:<\/strong><\/em><br \/>Matthew Wicklund, MD<\/p>\n<p><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06564974\">https:\/\/clinicaltrials.gov\/study\/NCT06564974<\/a><\/p>\n<p><strong>Type of Study:<\/strong><br \/>Observational\/Registry<\/p>\n<p><strong>Summary<\/strong><br \/>The goal of this observational study is to follow patients being treated with the FDA approved drug AGAMREE\u00ae in male patients 2 years of age or older with Duchenne&#8217;s Muscular Dystrophy for long term safety and quality of life. Patients will be followed for approximately 5 years in the registry and will return to the site for Yearly Follow-up Visits (+\/- 30 days) for registry assessments. Information on standard of care treatment and procedures for management of DMD will also be collected. Patients and\/or their parents\/legal guardians will be asked to complete paper QoL questionnaires at enrollment and at each Yearly Follow-up Visit (+\/- 30 days)<\/p>\n<p><strong>Link to Sponsor&#8217;s Website:<br \/><\/strong><a href=\"https:\/\/agamree.com\/agamree-summit-study\/\">https:\/\/agamree.com\/agamree-summit-study\/<\/a><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignright wp-image-4514\" src=\"https:\/\/lsom.uthscsa.edu\/neurology\/wp-content\/uploads\/sites\/105\/2024\/10\/Marlon-Tamayo-Muradas.jpg\" alt=\"\" width=\"104\" height=\"145\" \/><\/p>\n<p style=\"text-align: right\"><em><strong>Study Coordinator:<\/strong><\/em><br \/>Marlon Tamayo<br \/>Office: 210-450-7370<br \/>Email:\u00a0<a href=\"mailto:tomayomurada@uthscsa.edu\">tomayomurada@uthscsa.edu<\/a><\/p><\/div><\/li><li class=\"accordion-item \" data-accordion-item><a href=\"#\" class=\"accordion-title\"><h2>GRASP<\/h2><\/a><div class=\"accordion-content\" data-tab-content><p><p style=\"text-align: left\"><img loading=\"lazy\" decoding=\"async\" class=\"alignleft wp-image-3425\" src=\"https:\/\/lsom.uthscsa.edu\/neurology\/wp-content\/uploads\/sites\/105\/2023\/05\/3A4_19_13070105_1848520645_2.jpg\" alt=\"Matthew WIcklund, MD\" width=\"104\" height=\"145\" \/> \u00a0<\/p>\n<p style=\"text-align: left\"><em><strong>Principal Investigator:<\/strong><\/em><br \/>Matthew Wicklund, MD<\/p>\n<p><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT03981289\">https:\/\/clinicaltrials.gov\/study\/NCT03981289<\/a><\/p>\n<p><strong>Type of Study:<\/strong><br \/>Observational\/Registry<\/p>\n<p><strong>Summary<\/strong><br \/>Limb Girdle Muscular Dystrophy comprise a group of disorders made up of over 30 mutations which share a common phenotype of progressive weakness of the shoulder and hip girdle muscles. While the individual genetic mutations are rare, as a cohort, LGMDs are one of the four most common muscular dystrophies. The overall goal of project 1 is to define the key phenotypes as measured by standard clinical outcome assessments (COAs) for limb girdle muscular dystrophies (LGMD) to hasten therapeutic development.<\/p>\n<p><strong>Link to Sponsor&#8217;s Website:<br \/><\/strong><a href=\"https:\/\/www.mdcrn.com\/grasp\/network-information\">https:\/\/www.mdcrn.com\/grasp\/network-information<\/a><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignright wp-image-4514\" src=\"https:\/\/lsom.uthscsa.edu\/neurology\/wp-content\/uploads\/sites\/105\/2024\/10\/Marlon-Tamayo-Muradas.jpg\" alt=\"\" width=\"104\" height=\"145\" \/><\/p>\n<p style=\"text-align: right\"><em><strong>Study Coordinator:<\/strong><\/em><br \/>Marlon Tamayo<br \/>Office: 210-450-7370<br \/>Email:\u00a0<a href=\"mailto:tomayomurada@uthscsa.edu\">tomayomurada@uthscsa.edu<\/a><\/p><\/div><\/li><\/ul>[\/vc_column][vc_column width=&#8221;1\/6&#8243;][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column width=&#8221;2\/3&#8243;][vc_column_text css=&#8221;&#8221;] Expertise: We offer a robust research program including many Clinical trials and innovative research for patients with ALS, myasthenia gravis, muscular dystrophies, and peripheral neuropathy. We are an active member of the Northeast ALS Consortium (NEALS) and the Muscle Study Group (MSG).\u00a0 We are currently part of the Healey Platform study in [&hellip;]<\/p>\n","protected":false},"author":226,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-4930","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Neuromuscular Research - Department of Neurology<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/lsom.uthscsa.edu\/neurology\/neuromuscular-research-3\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Neuromuscular Research - Department of Neurology\" \/>\n<meta property=\"og:description\" content=\"[vc_row][vc_column width=&#8221;2\/3&#8243;][vc_column_text css=&#8221;&#8221;] Expertise: We offer a robust research program including many Clinical trials and innovative research for patients with ALS, myasthenia gravis, muscular dystrophies, and peripheral neuropathy. We are an active member of the Northeast ALS Consortium (NEALS) and the Muscle Study Group (MSG).\u00a0 We are currently part of the Healey Platform study in [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/lsom.uthscsa.edu\/neurology\/neuromuscular-research-3\/\" \/>\n<meta property=\"og:site_name\" content=\"Department of Neurology\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-02T22:22:37+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/lsom.uthscsa.edu\\\/neurology\\\/neuromuscular-research-3\\\/\",\"url\":\"https:\\\/\\\/lsom.uthscsa.edu\\\/neurology\\\/neuromuscular-research-3\\\/\",\"name\":\"Neuromuscular Research - Department of Neurology\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/lsom.uthscsa.edu\\\/neurology\\\/#website\"},\"datePublished\":\"2025-04-02T16:35:44+00:00\",\"dateModified\":\"2025-04-02T22:22:37+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/lsom.uthscsa.edu\\\/neurology\\\/neuromuscular-research-3\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/lsom.uthscsa.edu\\\/neurology\\\/neuromuscular-research-3\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/lsom.uthscsa.edu\\\/neurology\\\/neuromuscular-research-3\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/lsom.uthscsa.edu\\\/neurology\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Neuromuscular Research\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/lsom.uthscsa.edu\\\/neurology\\\/#website\",\"url\":\"https:\\\/\\\/lsom.uthscsa.edu\\\/neurology\\\/\",\"name\":\"Department of Neurology\",\"description\":\"Department of Neurology\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/lsom.uthscsa.edu\\\/neurology\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Neuromuscular Research - Department of Neurology","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/lsom.uthscsa.edu\/neurology\/neuromuscular-research-3\/","og_locale":"en_US","og_type":"article","og_title":"Neuromuscular Research - Department of Neurology","og_description":"[vc_row][vc_column width=&#8221;2\/3&#8243;][vc_column_text css=&#8221;&#8221;] Expertise: We offer a robust research program including many Clinical trials and innovative research for patients with ALS, myasthenia gravis, muscular dystrophies, and peripheral neuropathy. We are an active member of the Northeast ALS Consortium (NEALS) and the Muscle Study Group (MSG).\u00a0 We are currently part of the Healey Platform study in [&hellip;]","og_url":"https:\/\/lsom.uthscsa.edu\/neurology\/neuromuscular-research-3\/","og_site_name":"Department of Neurology","article_modified_time":"2025-04-02T22:22:37+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/lsom.uthscsa.edu\/neurology\/neuromuscular-research-3\/","url":"https:\/\/lsom.uthscsa.edu\/neurology\/neuromuscular-research-3\/","name":"Neuromuscular Research - Department of Neurology","isPartOf":{"@id":"https:\/\/lsom.uthscsa.edu\/neurology\/#website"},"datePublished":"2025-04-02T16:35:44+00:00","dateModified":"2025-04-02T22:22:37+00:00","breadcrumb":{"@id":"https:\/\/lsom.uthscsa.edu\/neurology\/neuromuscular-research-3\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/lsom.uthscsa.edu\/neurology\/neuromuscular-research-3\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/lsom.uthscsa.edu\/neurology\/neuromuscular-research-3\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/lsom.uthscsa.edu\/neurology\/"},{"@type":"ListItem","position":2,"name":"Neuromuscular Research"}]},{"@type":"WebSite","@id":"https:\/\/lsom.uthscsa.edu\/neurology\/#website","url":"https:\/\/lsom.uthscsa.edu\/neurology\/","name":"Department of Neurology","description":"Department of Neurology","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/lsom.uthscsa.edu\/neurology\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/lsom.uthscsa.edu\/neurology\/wp-json\/wp\/v2\/pages\/4930","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lsom.uthscsa.edu\/neurology\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/lsom.uthscsa.edu\/neurology\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/lsom.uthscsa.edu\/neurology\/wp-json\/wp\/v2\/users\/226"}],"replies":[{"embeddable":true,"href":"https:\/\/lsom.uthscsa.edu\/neurology\/wp-json\/wp\/v2\/comments?post=4930"}],"version-history":[{"count":0,"href":"https:\/\/lsom.uthscsa.edu\/neurology\/wp-json\/wp\/v2\/pages\/4930\/revisions"}],"wp:attachment":[{"href":"https:\/\/lsom.uthscsa.edu\/neurology\/wp-json\/wp\/v2\/media?parent=4930"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}